<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329483</url>
  </required_header>
  <id_info>
    <org_study_id>BagcilarTRH</org_study_id>
    <nct_id>NCT02329483</nct_id>
  </id_info>
  <brief_title>Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders</brief_title>
  <official_title>Early Follicular Phase Androstenedione Monitoring During Low-dose Step-up Induction of Ovulation in High Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to predefine the threshold FSH doses during the early follicular phases in&#xD;
      low- dose step-up ovulation induction cycles used to treat anticipated high responders by&#xD;
      monitoring total testosterone and androstenedione blood levels. The blood levels of total&#xD;
      testosterone and androstenedione levels will be measured in patients at the starting day and&#xD;
      at every control day when vaginal sonographic folliculometries and blood estradiol&#xD;
      measurements are made. Hence, we are aiming to define an early monitoring parameter by which&#xD;
      we will be able to define a follicular response to treatment before estradiol rise or&#xD;
      apparently selected follicular growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 patients with anticipated high ovarian response, who are being planned to be&#xD;
      conventionally treated with low-dose step-up ovulation induction and intrauterine&#xD;
      insemination will be analysed in this study. At every control day including the start day,&#xD;
      blood samples taken for blood estradiol (and if required progesterone) measurements will be&#xD;
      used to measure blood androstenedione and total testosterone levels, as well. Hence, we will&#xD;
      have defined an early parameter for defining follicular response in the first 5-7 days of&#xD;
      low-dose step-up ovulation induction. Low-dose step-up ovulation induction will be started at&#xD;
      50-75Units/day of rhFSH and the dose will be increased at not earlier than the 7th day at an&#xD;
      increment of +37,5Units/day unless a response is observed ( which is at least a 10mm&#xD;
      follicle, selected for growth). If more than 3 dominant follicles are selected, the cycle&#xD;
      will be cancelled. Otherwise, when at least one follicle &gt;16mm is obtained, a 150Microgram&#xD;
      sc. injection will be administered for ovulation trigger and intrauterine insemination made&#xD;
      at the 34th-36th hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood androstenedione and testosterone levels.</measure>
    <time_frame>within 10-20 days</time_frame>
    <description>Patterns of blood androstenedione and testosterone levels with respect to the regular monitoring parameters and relations to secondary outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy</measure>
    <time_frame>20-30 days</time_frame>
    <description>blood hCG level &gt;10mIU/mlt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle cancellation</measure>
    <time_frame>within 10-20 days</time_frame>
    <description>cancellation of treatment despite 2 rounds of dose step-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian hyperstimulation</measure>
    <time_frame>10-30 days</time_frame>
    <description>Enlarged ovaries, abdominal ascites, pleural effusion, hemoconcentration, abdominal swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for dose step-up</measure>
    <time_frame>7-14 days</time_frame>
    <description>if at the 7th day of a dose, no follicle(s)&gt;10mm are observed then the dose is increased</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Infertility</condition>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>High responder infertile patients</arm_group_label>
    <description>Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary/Secondary Infertile patients (couples); ovarian high response to ovulation&#xD;
        induction anticipated; with mild male factor or without any male factor.&#xD;
        Hysterosalpingography reveals patent uterine tubes and normal uterine cavity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary/Secondary infertile women; aged 20-35 years of age&#xD;
&#xD;
          -  High ovarian response to ovulation induction anticipated.(Antral follicle count on the&#xD;
             3rd day of cycle&gt;10)&#xD;
&#xD;
          -  Mild male factor or normal sperm parameters&#xD;
&#xD;
          -  Normal anatomic findings with the HSG&#xD;
&#xD;
          -  Eugonadotropic&#xD;
&#xD;
          -  Normal blood prolactin and TSH levels&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Amenorrheic women&#xD;
&#xD;
          -  Women with Diabetes Mellitus&#xD;
&#xD;
          -  Body Mass Index: &lt;22 or &gt;30&#xD;
&#xD;
          -  Age&lt;20 or &gt;35 years old&#xD;
&#xD;
          -  Hormonal abnormalities: regarding prolactin, TSH&#xD;
&#xD;
          -  Hypo- or Hypergonadotropic women&#xD;
&#xD;
          -  Additional medical or surgical disease&#xD;
&#xD;
          -  Ovarian cysts&#xD;
&#xD;
          -  Previous ovarian surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eser S Ozyurek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erdal Kaya, Prof Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa U Karacaoglu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evrim E Kovalak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erdinc Ergul, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eser S Ozyurek, MD</last_name>
    <phone>+905309322345</phone>
    <email>eozyurek@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bagcilar Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eser S Ozyurek, MD</last_name>
      <phone>+905309322345</phone>
      <email>eozyurek@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Mustafa U Karacaoglu, MD</last_name>
      <email>dr.uner@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>December 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>April 4, 2015</last_update_submitted>
  <last_update_submitted_qc>April 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bagcilar Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Eser Sefik Ozyurek</investigator_full_name>
    <investigator_title>Operator Doctor</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Ovulation induction</keyword>
  <keyword>Low-dose step-up protocol</keyword>
  <keyword>Ovarian high responder</keyword>
  <keyword>Androgens</keyword>
  <keyword>Androstenedione</keyword>
  <keyword>Testosterone</keyword>
  <keyword>rhFSH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

